Study on Sacituzumab Govitecan and Cetuximab for Head and Neck Squamous Cell Cancer

Inclusion Criteria

• Diagnosed with squamous cell carcinoma of the head and neck, including areas like the sinuses, nasal cavity, mouth, throat, and voice box.
• Have advanced cancer that cannot be cured with surgery or radiation.
• Cancer has progressed after first-line treatment with anti-PD(L)1 therapy, with or without chemotherapy.
• HPV status for throat cancer must be confirmed or tested during the study.
• Have measurable cancer based on specific criteria.
• Be 18 years or older.
• Be in good overall health with a performance status of 0 or 1.
• Have adequate blood cell counts and organ function based on recent tests.
• Women must not be pregnant or breastfeeding and must agree to use effective birth control during and after the study.
• Men must agree to use contraception and not donate sperm during and after the study.
• Must provide informed consent to participate.

Exclusion Criteria

• Have received more than two prior treatments for recurrent/metastatic cancer.
• Have had severe allergic reactions to similar treatments.
• Have previously received certain cancer drugs for HNSCC.
• Have a diagnosis of Gilbert's Syndrome.
• Have had recent cancer treatments or not fully recovered from previous treatments.
• Have other active cancers unless approved by the study doctor.
• Have serious health conditions like recent heart problems or severe infections.
• Have active brain cancer or untreated brain metastases.
• Have certain immune system disorders or infections like HIV or hepatitis.
• Use herbal remedies that may interfere with treatment.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.